Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
AssigneeIDEXX Laboratories, Inc.
InventorsEugene Regis Krah, III, Melissa Beall, Thomas Patrick O'Connor, Jr., Ramaswamy Chandrashekar
Life of this patent
Estimating the term…
Abstract
The invention provides Ehrlichia canis antigens that can be used to detect E. canis infected animals regardless of whether the animals have been vaccinated for E. canis. The invention also provides compositions and methods for determining the presence of E. canis antigens and antibodies.
Claims12
A method of distinguishing between animals that have been (a) infected with Ehrlichia canis;
- and (b) animals that have not been infected with E. canis regardless of whether the animal has been vaccinated for E. canis, the method comprising:
- (a) contacting a biological sample from an animal with one or more purified polypeptides that do not specifically bind to antibodies that are a component of the animal's immune response to an E. canis vaccine;
- wherein the one or more purified polypeptides comprise SEQ ID NOs:
- 22, 23, 24, 24, 25, 27, 28, 29, 30, 31, 32, or 33, wherein the one or more purified polypeptides are 15 to 75 amino acids in length ;
- and
- (b) detecting whether antibodies in the biological sample specifically bind to the one or more purified E. canis polypeptides;
- wherein, if antibodies in the biological sample specifically bind to the one or more purified polypeptides, then the animal has been infected with E. canis.
A method for determining the presence or absence of an antibody or antigen-binding fragments thereof that are specific for E. canis, in a test sample, wherein the antibody or antigen-binding fragments specifically bind to one or more purified polypeptides consisting of the amino acid sequence set forth in SEQ ID NOs:
- 22-33 or combinations thereof comprising:
- (a) contacting the test sample with one or more purified polypeptides comprising SEQ ID NOs:
- 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, or 33 wherein the one or more purified polypeptides are 15 to 75 amino acids in length, and wherein the one or more purified polypeptides specifically bind an antibody that is specific for E. canis, under conditions suitable for specific binding of the one or more purified polypeptides to the antibodies or antigen-binding fragments thereof;
- and
- (b) detecting the presence of specific binding of the one or more purified polypeptides to the antibodies or antigen-binding fragments thereof;
- wherein the presence of specific binding of the one or more purified polypeptides to the antibodies or antigen-binding fragments indicates the presence of the antibodies or antigen-binding fragments thereof specific for E. canis in the test sample and wherein the absence of specific binding indicates the absence of the antibody or antigen binding fragments.
A method of distinguishing between an animal that has been infected with E. canis from an animal that has not been infected with E. canis, comprising:
- (a) contacting a biological sample from an animal with one or more purified polypeptides wherein the one or more purified polypeptides comprise SEQ ID NOs:
- 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, or 33, wherein the one or more purified polypeptides are 15 to 75 amino acids in length ;
- and
- (b) detecting whether antibodies in the biological sample specifically bind to the one or more purified polypeptides;
- wherein, if antibodies in the biological sample specifically bind to the one or more purified polypeptides, then the animal has been infected with E. canis.
Dependencies are inferred from the claim text.